|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
22
|
|
pubmed:dateCreated |
2009-11-20
|
|
pubmed:abstractText |
Restoring p53 function by antagonizing its interaction with the negative regulator MDM2 is an appealing nongenotoxic approach to treating tumors with wild-type p53. Mutational inactivation of p53 is rare in neuroblastoma tumors at diagnosis and occurs in only a subset of multidrug-resistant neuroblastomas.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Casp3 protein, mouse,
http://linkedlifedata.com/resource/pubmed/chemical/Caspase 3,
http://linkedlifedata.com/resource/pubmed/chemical/Caspase 7,
http://linkedlifedata.com/resource/pubmed/chemical/Imidazoles,
http://linkedlifedata.com/resource/pubmed/chemical/MDM2 protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Piperazines,
http://linkedlifedata.com/resource/pubmed/chemical/Proto-Oncogene Proteins c-mdm2,
http://linkedlifedata.com/resource/pubmed/chemical/Tumor Suppressor Protein p53,
http://linkedlifedata.com/resource/pubmed/chemical/nutlin 3
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Nov
|
|
pubmed:issn |
1460-2105
|
|
pubmed:author |
pubmed-author:BrackeMarcM,
pubmed-author:CinatlJindrichJJr,
pubmed-author:CuvelierClaude ACA,
pubmed-author:De PaepeAnneA,
pubmed-author:FerdinandeLiesbethL,
pubmed-author:LambertzIrinaI,
pubmed-author:MarineJean-ChristopheJC,
pubmed-author:MichaelisMartinM,
pubmed-author:RihaniAliA,
pubmed-author:SpelemanFrankF,
pubmed-author:TaildemanJasmienJ,
pubmed-author:Van MaerkenTomT,
pubmed-author:VandesompeleJoJ,
pubmed-author:VercruysseLiesbethL,
pubmed-author:YigitNurtenN
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
18
|
|
pubmed:volume |
101
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1562-74
|
|
pubmed:meshHeading |
pubmed-meshheading:19903807-Administration, Oral,
pubmed-meshheading:19903807-Animals,
pubmed-meshheading:19903807-Antineoplastic Agents,
pubmed-meshheading:19903807-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:19903807-Caspase 3,
pubmed-meshheading:19903807-Caspase 7,
pubmed-meshheading:19903807-Cell Cycle,
pubmed-meshheading:19903807-Cell Line, Tumor,
pubmed-meshheading:19903807-DNA Fragmentation,
pubmed-meshheading:19903807-Diploidy,
pubmed-meshheading:19903807-Drug Resistance, Neoplasm,
pubmed-meshheading:19903807-Female,
pubmed-meshheading:19903807-Gene Expression Regulation, Neoplastic,
pubmed-meshheading:19903807-Humans,
pubmed-meshheading:19903807-Imidazoles,
pubmed-meshheading:19903807-Immunoblotting,
pubmed-meshheading:19903807-Immunohistochemistry,
pubmed-meshheading:19903807-Mice,
pubmed-meshheading:19903807-Mice, Nude,
pubmed-meshheading:19903807-Mutation,
pubmed-meshheading:19903807-Neuroblastoma,
pubmed-meshheading:19903807-Piperazines,
pubmed-meshheading:19903807-Proto-Oncogene Proteins c-mdm2,
pubmed-meshheading:19903807-Reverse Transcriptase Polymerase Chain Reaction,
pubmed-meshheading:19903807-Transplantation, Heterologous,
pubmed-meshheading:19903807-Tumor Suppressor Protein p53
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
Antitumor activity of the selective MDM2 antagonist nutlin-3 against chemoresistant neuroblastoma with wild-type p53.
|
|
pubmed:affiliation |
Center for Medical Genetics, Ghent University Hospital, Ghent, Belgium. tom.vanmaerken@ugent.be
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
